Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Companies

News : Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESO

10/26/2020 | 05:57pm EST

NEW YORK, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mesoblast Limited (“Mesoblast” or the “Company”) (NASDAQ: MESO). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Mesoblast and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 1, 2020, Mesoblast issued a press release announcing “that the US Food and Drug Administration (FDA) has issued a Complete Response Letter to its Biologics License Application (BLA) for remestemcel-L for the treatment of pediatric steroid-refractory acute graft versus host disease (SR-aGVHD).” Mesbolast advised investors that “[w]hile the Oncologic Drugs Advisory Committee (ODAC)1 of the FDA voted 9:1 that the available data support the efficacy of remestemcel-L in pediatric patients with SR-aGVHD, the FDA recommended that Mesoblast conduct at least one additional randomized, controlled study in adults and/or children to provide further evidence of the effectiveness of remestemcel-L for SR-aGVHD.” 

On this news, Mesoblast’s stock price fell $6.56 per share, or 35.29%, to close at $12.03 per share on October 2, 2020.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980


© GlobeNewswire 2020
Latest news "Companies"
03:37aWEST JAPAN RAILWAY : Monthly Data Updated
PU
03:37aBASICNET S P A : Here goes the 5th BasicBusinessWeek,...
PU
03:37aELOS MEDTECH : Celebrating 10 years in China and looking forward to the decade ahead
PU
03:35aWOODSIDE PETROLEUM : pre-empts FAR's Sangomar transaction
PU
03:35aDEVEX RESOURCES : Change in substantial holding - T Goyder
PU
03:33aIrish foreign minister sees 'good chance' of Brexit deal within days
RE
03:33aOil gains as OPEC+ resumes output cut extension talks after impasse
RE
03:33aRIB SOFTWARE : RIB) signs a Phase-II-contract (No. 35 / 2020) with ECOSOIL Holding GmbH
EQ
03:32aGETINGE : introduces new inner racks for stainless steel DPTE® Beta Containers
PU
03:32aSWMA DEC 3, 2020 9 : 05 AM CET + 0.5 % 663.60 SEK The share
PU
Latest news "Companies"